Search - tctmd.com

Displaying 1 - 20 of 84

Sort: Relevancy | Date

Presentation TCT 2024

Role of Inflammation in Coronary Heart Disease: Why Does it Matter

Presenter: Deepak Bhatt

October 29, 2024

Presentation TCT 2024

Inflammation- Current and Emerging Therapeutic Landscape

Presenter: Deepak Bhatt

October 29, 2024

Presentation TCT 2022

Long-Term Outcomes Following Catheter-Based Renal Denervation in Patients With Uncontrolled Hypertension: 3-Year Follow-up of the SYMPLICITY HTN-3 Trial

Presenter: Deepak Bhatt

September 18, 2022

Presentation TCT 2021

Finding the Sweet Spot: Balancing Reducing Ischemic Risk and Reducing Bleeding Risk with Antiplatelet Therapy

Presenter: Deepak Bhatt

November 05, 2021

Presentation TCT 2021

Antiplatelet Therapy for Patients with Diabetes Undergoing PCI

Presenter: Deepak Bhatt

November 05, 2021

Presentation ACC 2021

Benefits of SGLT1/2 Inhibition with Sotagliflozin in Heart Failure With Preserved Ejection Fraction

Presenter: Deepak L. Bhatt

May 17, 2021

Presentation ACC 2020

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presenter: Deepak L. Bhatt

March 30, 2020

Presentation ESC 2019

THEMIS: Ticagrelor Added to Aspirin in Patients with Stable Coronary Disease and Diabetes

Presenter: Deepak Bhatt

September 01, 2019

Presentation Fellows 2019

The Evolution in PCI Pharmacology Over the Past 25 Years

Presenter: Deepak L. Bhatt

April 12, 2019

Presentation ACC 2019

First Randomized Human Experience with a Ticagrelor Reversal Agent

Presenter: Deepak L. Bhatt

March 18, 2019

Presentation AHA 2018

REDUCE-IT Trial: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presenter: Deepak L Bhatt

November 16, 2018

Presentation TCT 2018

Flash Debate #1: Based on What We Dont Know - Culprit Lesion Only PCI With a Conservative Approach Is the Preferred Strategy!

Presenter: Anthony H. Gershlick, Pieter C. Smits, Deepak L. Bhatt

September 24, 2018

Presentation TCT 2018

ESC 2018 Late Breaking Trial #2 - MitraFR: What I Liked and What I Question

Presenter: Deepak L. Bhatt, Gregg W. Stone, Stephan Windecker

September 23, 2018

Presentation TCT 2018

ESC 2018 Late Breaking Trial #1 Global Leaders: What I Liked and What I Question

Presenter: Deepak L. Bhatt, Gregg W. Stone, Giuseppe Biondi-Zoccai

September 23, 2018

Presentation TCT 2018

ACC 2018 Late Breaking Trial #2- COMPASS : What I Liked and What I Question

Presenter: Deepak L. Bhatt, Gregg W. Stone, Kurt Huber

September 23, 2018

Presentation TCT 2018

ACC 2018 Late Breaking Trial #1 - ODYSSEY Outcomes: What I Liked and What I Question

Presenter: Deepak L. Bhatt, Gregg W. Stone, Otavio Berwanger, Peter Juni, Sanjay Kaul, Roxana Mehran, E. Magnus Ohman, Stuart J. Pocock, Giulio Stefanini

September 23, 2018

Presentation TCT 2018

COMPASS Trial Revisited: Weighing Rivaroxaban Secondary Prevention vs DAPT After PCI

Presenter: Deepak L. Bhatt, Tullio Palmerini, Michael Maeng

September 23, 2018

Presentation TCT 2018

Ultra-Short DAPT (1 3 Months): For Which Patients and Stents Do We Have Evidence?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Philip M. Urban

September 23, 2018

Presentation TCT 2018

Patient Selection for Prolonged DAPT: Risk Scores or Wise Clinical Judgement?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Usman Baber

September 23, 2018

Presentation TCT 2018

Who Is the High Bleeding Risk Patient, and How Should DAPT Duration Be Weighed Against Ischemic Risk?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Roxana Mehran

September 23, 2018

Advertisement

Role of Inflammation in Coronary Heart Disease: Why Does it Matter

Inflammation- Current and Emerging Therapeutic Landscape

Long-Term Outcomes Following Catheter-Based Renal Denervation in Patients With Uncontrolled Hypertension: 3-Year Follow-up of the SYMPLICITY HTN-3 Trial

Finding the Sweet Spot: Balancing Reducing Ischemic Risk and Reducing Bleeding Risk with Antiplatelet Therapy

Antiplatelet Therapy for Patients with Diabetes Undergoing PCI

Benefits of SGLT1/2 Inhibition with Sotagliflozin in Heart Failure With Preserved Ejection Fraction

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

THEMIS: Ticagrelor Added to Aspirin in Patients with Stable Coronary Disease and Diabetes

The Evolution in PCI Pharmacology Over the Past 25 Years

First Randomized Human Experience with a Ticagrelor Reversal Agent

REDUCE-IT Trial: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Flash Debate #1: Based on What We Dont Know - Culprit Lesion Only PCI With a Conservative Approach Is the Preferred Strategy!

ESC 2018 Late Breaking Trial #2 - MitraFR: What I Liked and What I Question

ESC 2018 Late Breaking Trial #1 Global Leaders: What I Liked and What I Question

ACC 2018 Late Breaking Trial #2- COMPASS : What I Liked and What I Question

ACC 2018 Late Breaking Trial #1 - ODYSSEY Outcomes: What I Liked and What I Question

COMPASS Trial Revisited: Weighing Rivaroxaban Secondary Prevention vs DAPT After PCI

Ultra-Short DAPT (1 3 Months): For Which Patients and Stents Do We Have Evidence?

Patient Selection for Prolonged DAPT: Risk Scores or Wise Clinical Judgement?

Who Is the High Bleeding Risk Patient, and How Should DAPT Duration Be Weighed Against Ischemic Risk?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content